The poster presentation, titled The Effect of the GLP-1 Agonist ROSE-010 on Food Consumption in Subjects with Overweight and Obesity: A Randomized Controlled Clinical Trial, will share results from a blinded, placebo-controlled Phase 2a study evaluating multiple doses of ROSE-010 on mealtime food intake, caloric reduction, GI side effects, satiety, safety, and weight loss
By attenuating iNOS and shifting arginine metabolism toward NO bioavailability and reduced ADMA levels, GLP-1RAs can enhance epithelial barrier function and mitigate ROS generation
In Stock Retatrutide 60MG is a 60-milligram format of retatrutide, a synthetic peptide investigated as a multi receptor agonist in metabolic research
Current Pharmaceutical Design, 17 (16), 16121632